{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T14:37:26Z","timestamp":1753886246822,"version":"3.40.5"},"reference-count":110,"publisher":"Informa UK Limited","issue":"6","funder":[{"name":"paper was funded by the Strategic Plan - Center for Innovative Biomedicine and Biotechnology funds via Portuguese Foundation for Science and Technology (FCT) under Project","award":["UIDB\/04539\/2020"],"award-info":[{"award-number":["UIDB\/04539\/2020"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2023,6,3]]},"DOI":"10.1080\/13543776.2023.2240025","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T17:26:49Z","timestamp":1690392409000},"page":"397-420","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia \u2013 a patent review"],"prefix":"10.1080","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7193-4025","authenticated-orcid":false,"given":"Andr\u00e9 T. S.","family":"Vicente","sequence":"first","affiliation":[{"name":"Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0779-6083","authenticated-orcid":false,"given":"Jorge A.R.","family":"Salvador","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal"},{"name":"Center for Neuroscience and Cell Biology (CNC), Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal"}]}],"member":"301","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2152"},{"key":"cit0002","unstructured":"Human Proteome Map. [cited 2023 Feb 7]. Available from: http:\/\/www.humanproteomemap.org\/"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-061516-044908"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1039\/D2CS00220E"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00365-x"},{"key":"cit0006","unstructured":"Blood Cancers - Hematology.org. [accessed 2023 Mar 2]. https:\/\/www.hematology.org\/education\/patients\/blood-cancers"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.25.2.91"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106156"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01204-6"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.3390\/cells10010117"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114442"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20246141"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26837"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1038\/306277a0"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(84)90077-1"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0230-9"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1126\/science.3460176"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(84)90438-0"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1126\/science.2406902"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1038\/386732a0"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1567"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1038\/nsb747"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90148-R"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.10.3343"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1038\/329851a0"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01082-4"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116786"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.26"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14010215"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.3109\/02841868309134332"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1981.tb03534.x"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11223"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V69.3.961.961"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)92737-4"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197902153000702"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.9.3691"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.04.016"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2015.1012155"},{"key":"cit0042","unstructured":"Zimmermann J, Sutter B, Burger HM, inventors; Novartis, assignee. Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use. Patent WO 99\/03854 p. A1; 1999."},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr060"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1068"},{"key":"cit0046","unstructured":"Das J, Padmanabha R, Chen P, et al., inventors; Bristol-myers squibb company, assignee. cyclic protein tyrosine kinase inhibitors. Patent WO 2004\/085388 A2; 2004."},{"key":"cit0047","unstructured":"Hewes B, Inventor W, assignee. Treatment of imatinib resistant leukemia. Patent WO 2008\/150957 A2; 2008."},{"key":"cit0048","unstructured":"Gallagher N, Yin O, inventors; Novartis AG, assignee. Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, C-Kit, Ddr1, Ddr2 or Pdgf-R Kinase Activity. Patent WO 2011\/062927 A1; 2011."},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480"},{"key":"cit0050","unstructured":"Murray CK, Rozamus LW, Chaber JJ, et al. inventors; Ariad Pharmaceuticals, Inc., assignee. synthetic methods for preparing 3-(Imidazo[1,2-B]pyridazin-3-Ylethynyl)-4-Methyl-N-{4-[(4-Methylpiperazin-1-Yl)methyl]-3-(Trifluoromethyl)phenyl}benzamide mono hydrochloride, other salt forms of this compound and intermediates thereof. Patent WO 2014\/093583 A2; 2014."},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.09.028"},{"key":"cit0052","unstructured":"Dodd SK, Furet P, Grotzfeld RM, et al., inventors; Novartis AG, assignee. Benzamide derivatives for inhibiting the activity of Abl1, Abl2 and Bcr-Abl1. Patent WO 2013\/171639 A1; 2013."},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1038\/nature21702"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810328"},{"key":"cit0055","unstructured":"Kenten JH, Roberts SF, inventors; Proteinix, Inc., assignee. Controlling protein levels in eucaryotic organisms. Patent US6559280B2; 2003."},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114290"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1007\/s00044-022-02882-2"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.3390\/biom12091257"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00371-6"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.141230798"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1039\/D2CS00193D"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.7b00252"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2056"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2013.12.003"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2022.103395"},{"key":"cit0066","unstructured":"Crews CM, Buckley D, Ciulli A, et al., inventors; Yale University; GlaxoSmithKline Intelectual Property Development Ltd.; Cambridge Enterprise Limited University of Cambridge, assignee. Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase. Patent US10730862B2; 2014."},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1039\/D2CS00387B"},{"key":"cit0068","unstructured":"D\u2019Amato R, inventor; Childern\u2019s medical center corporation, assignee. methods and composition for inhibition of angiogenesis. Patent US8012996B2; 2011."},{"key":"cit0069","unstructured":"Muller GW, Stirling DI, Chen RSC, inventors; Celgene Corporation, assignee. Isoindolines, method of use, and pharmaceutical compositions. Patent US6555554B2; 2003"},{"key":"cit0070","unstructured":"Silverman RI, inventor; Concert Pharmaceuticals, Inc., assignee. Deuterated Dasabuvir. Patent WO 2016\/105547 A1; 2016."},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2022.1999415"},{"key":"cit0072","unstructured":"Umezawa H, Aoyagi T, Takeuchi T, et al., inventors; Microbial chemistry research foundation, assignee. biologically active substance, bestatin, and production thereof. Patent US4029547A; 1977."},{"key":"cit0073","unstructured":"Mainolfi N, Ji N, Kluge AF, et al., inventors; Kymera Therapeutics, Inc., assignee. IRAK degraders and uses thereof. Patent US10874743B2; 2020."},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.02.006"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911068"},{"key":"cit0076","unstructured":"Haley GJ, Kong N, Liu EA, et al., inventors; F, inventors; FHoffMannLa Roche AG, assignee. HoffMannLa Roche AG, assignee. Novel Cis-Imidazolines. Patent WO 2005\/123691 A1; 2005."},{"key":"cit0077","unstructured":"Bartkovitz DJ, Chu X, Ding Q, et al., inventors; HoffmannLa Roche, Inc., assignee. , inventors; HoffmannLa Roche, Inc., assignee. Substituted pyrrolidine-2-carboxamides. Patent US8354444B2; 2013."},{"key":"cit0078","unstructured":"Rao H, inventor; Board of Regents, The University of Texas System, assignee. Compositions and methods for cancer therapy. Patent WO 2021\/007286 A1; 2019."},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2022.105848"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202100270"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1002\/med.21877"},{"key":"cit0082","unstructured":"Deshaies RJ, Crews C, Sakamoto KM, et al. Proteolysis targeting chimeric pharmaceutical. US7041298B2; 2002."},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114838"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00999-9"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00924-z"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.851087"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153778"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2021.1840553"},{"key":"cit0089","unstructured":"Crews C, Toure M, Ko E, et al., inventors; Yale University, assignee. Proteolysis targeting chimera compounds and methods of preparing and using same. Patent WO 2017\/079267 A1; 2017."},{"key":"cit0090","unstructured":"Phillips AJ, Nasveschuk CG, Henderson JA, et al., inventors; C4 Therapeutics, Inc., assignee. Heterocyclic degronimers for target protein degradation. Patent WO 2017\/197055 A1; 2017."},{"key":"cit0091","unstructured":"Phillips AJ, Nasveschuk CG, Henderson JA, et al., inventors; C4 Therapeutics, Inc., assignee. Preparation of spirocyclic degronimers for target protein degradation. WO 2017\/197036 A1; 2017"},{"key":"cit0092","unstructured":"Phillips Andrew J, Nasveschuk Chris G, Henderson James A, et al. C3-carbon linked glutarimide degronimers for target protein degradation. Patent WO2017197046A1; 2017."},{"key":"cit0093","unstructured":"Phillips AJ, Nasveschuk CG, Henderson JA, et al., inventors; C4 Therapeutics, Inc., assignee. Preparation of amine-linked C3-glutarimide degronimers for target protein degradation. Patent WO 2017\/197051 A1; 2017."},{"key":"cit0094","unstructured":"Phillips AJ, Nasveschuk CG, Henderson JA, et al., inventors; C4 Therapeutics, Inc., assignee. N\/O-Linked degrons and degronimers for protein degradation. Patent WO 2018\/237026 A1; 2018"},{"key":"cit0095","unstructured":"Yang X, Jiang B, Yin Q, et al., inventors; ShanghaiTech University, assignee. Protein Degradation Targeting Bcr-Abl Compound And Antitumor Application Thereof. Patent WO 2019\/19170150 A1; 2019."},{"key":"cit0096","unstructured":"Cai J, Li G, Chen Z, et al., inventors; Sichuan KelunBiotech Biopharmaceutical Co., Ltd., assignee. , inventors; Sichuan KelunBiotech Biopharmaceutical Co., Ltd., assignee. Multifunctional compound, preparation method therefor, and application thereof in pharmaceuticals. Patent WO 2019\/201123 A1; 2019."},{"key":"cit0097","unstructured":"Crews CM, Burslem G, inventors; Yale University, assignee. Allosteric Bcr-abl proteolysis targeting chimeric compounds. Patent WO 2020\/198055 A1; 2020."},{"key":"cit0098","unstructured":"You Q, Jiang Z, Wang Y, et al. inventors; China Pharmaceutical University, assignee. Proteolysis targeting chimeric molecule, preparation method, and application. Patent WO 2020\/151229 A1; 2020."},{"key":"cit0099","unstructured":"Phillips AJ, Nasveschuk CG, Henderson JA, et al., inventors; C4 Therapeutics, Inc., assignee. Targeted protein degradation. Patent WO 2020\/132561 A1; 2020."},{"key":"cit0100","unstructured":"Cheng L, Zeng S, Tu L, inventors; Sichuan Haisco Pharmaceutical Co., Ltd., assignee et al. Compound capable of degrading Bcr-Abl or PARP as well as preparation method and pharmaceutical application thereof. Patent CN113292536A; 2021."},{"key":"cit0101","unstructured":"Wei W, Jin J, Kaniskan HU, inventors; Beth Israel Deaconess Medical Center, Inc.; Icahn School of Medicine at Mount Sinai, assignees et al. Photo induced control of protein destruction. Patent WO 2021\/016521 A1; 2021."},{"key":"cit0102","unstructured":"Kang C, Hung W, Keller TH, et al. inventors; Agency for Science, Technology and Research, assignee. Therapeutic compounds and methods of use thereof.Patent WO 2021\/061053 A1; 2021."},{"key":"cit0103","unstructured":"Xiaoyun L, Ke D, Zhang Z, et al., inventors; Jinan University, assignee. Protein degradation targeting chimera and application thereof. Patent CN113372342A; 2021."},{"key":"cit0104","unstructured":"Lei M, Peng L, Luo Y, et al., inventors; Medshine Discovery, Inc., assignee. Proteolysis regulator and method for using same. Patent WO 20211\/85291 A1; 2021."},{"key":"cit0105","unstructured":"Winter G, Mayor RC, Kubicek S, inventors ; Research Center for Molecular Medicine of the Austrian Academy of Sciences, assignee. Oxazole and Thioazole-type cullin ring ubiquitin ligase compounds and uses thereof Patent WO 2021\/074414 A1; 2021."},{"key":"cit0106","unstructured":"Liyan C, Shenxin Z, Linglan T, et al. inventors; Hangzhou Medical College, assignee. Compound for inducing BCR-ABL protein degradation through targeted ubiquitination and application thereof. Patent CN114044775A; 2022."},{"key":"cit0107","unstructured":"Shenxin Z, Wenhai H, Zunyuan W, et al. inventors; Hangzhou Medical College, assignee. Bifunctional molecule for inducing BCR-ABL protein degradation based on VHL ligand as well as preparation method and application of bifunctional molecule. Patent CN115028678A; 2022."},{"key":"cit0108","unstructured":"Wegrzyniak E, Mcintosh J, Kato D, et al., inventors; Nurix Therapeutics, Inc.; Wegrzyniak E, assignee. Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use Patent WO 2022\/235698 p. A1; 2022."},{"key":"cit0109","unstructured":"Nasveschuk CG, Anderson CD, Henderson JA, et al., inventors; C4 Therapeutics, Inc., assignee. Tricyclic heterobifunctional compounds for degradation of targeted proteins. Patent WO 2022\/081928 A1; 2022."},{"key":"cit0110","unstructured":"Dahua C, Beibei Z, Pengfei X, et al., inventors; Yunnan University, assignee. Application of dasabuvir as novel ligand of E3 ligase to construction of PROTAC. Patent CN115089588A; 2022."}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2023.2240025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T14:33:03Z","timestamp":1691418783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2023.2240025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,3]]},"references-count":110,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,3]]}},"alternative-id":["10.1080\/13543776.2023.2240025"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2023.2240025","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"type":"print","value":"1354-3776"},{"type":"electronic","value":"1744-7674"}],"subject":[],"published":{"date-parts":[[2023,6,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-03-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}